Sort
4,870 grants matching “glp 1”
Phase 2 Study: Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome [IND 121109 acknowledged 8/27/14]
$435,569Eric Hollander · Albert Einstein College Of Medicine · R01 · FY2018 · FD
A NOVEL TARGETED DELIVERY SYSTEM FOR CANCER TREATMENT AND DIAGNOSIS
$435,490David Bramhill · Endurx Pharmaceuticals, Inc. · R44 · FY2016 · CA
Novel metabolic actions of GIP
$434,994Jonathan E Campbell · Duke University · R01 · FY2022 · DK
Overcoming the blood-brain barrier with nanoparticle vaccines against gliomas
$434,992Elias Sayour · University Of Florida · R37 · FY2023 · CA
IND-enabling preclinical development of a multipurpose intravaginal ring for the prevention of Herpes, HIV and unintended pregnancy
$434,962Thomas J. Smith · Auritec Pharmaceuticals, Inc. · R61 · FY2018 · AI
Molecular Basis of Antidiabetogenic Hormone Action
$434,912George G Holz · Upstate Medical University · R01 · FY2015 · DK
Molecular Basis of Antidiabetogenic Hormone Action
$434,462George G Holz · Upstate Medical University · R01 · FY2014 · DK
Biobehavioral Prediction of Illness Trajectory in Bulimic Syndromes
$433,833Pamela K. Keel · Florida State University · R01 · FY2019 · MH
IND-enabling preclinical development of a multipurpose intravaginal ring for the prevention of Herpes, HIV and unintended pregnancy
$433,812Thomas J. Smith · Auritec Pharmaceuticals, Inc. · R61 · FY2019 · AI
Novel Long Acting rhTSH Superagonist Analogs for Improved Diagnostic Imaging, Thyroglobulin Stimulation and Therapy of Thyroid Cancer.
$433,685Bruce Dale Weintraub · Trophogen, Inc. · R44 · FY2020 · CA
Role of slowly digestible starch in diabetes risk factors in pre-diabetic people
$433,140Eric Ravussin · Lsu Pennington Biomedical Research Ctr · R01 · FY2012 · DK
XENIN-25: NOVEL REGULATOR OF INSULIN SECRETION AND B-CELL FUNCTION
$432,606Burton M Wice · Washington University · R01 · FY2013 · DK
Glutamatergic Neurons in the Arcuate Nucleus (ARC) and Regulation of Satiety
$432,500Bradford B Lowell · Beth Israel Deaconess Medical Center · R01 · FY2019 · DK
Glutamatergic Neurons in the Arcuate Nucleus (ARC) and Regulation of Satiety
$432,500Bradford B Lowell · Beth Israel Deaconess Medical Center · R01 · FY2020 · DK
Glutamatergic Neurons in the Arcuate Nucleus (ARC) and Regulation of Satiety
$432,500Bradford B Lowell · Beth Israel Deaconess Medical Center · R01 · FY2018 · DK
Glutamatergic Neurons in the Arcuate Nucleus (ARC) and Regulation of Satiety
$432,500Bradford B Lowell · Beth Israel Deaconess Medical Center · R01 · FY2017 · DK
Glutamatergic Neurons in the Arcuate Nucleus (ARC) and Regulation of Satiety
$432,500Bradford B Lowell · Beth Israel Deaconess Medical Center · R01 · FY2016 · DK
Glomerular and Tubular Function in the Diabetic Kidney
$432,346Scott C. Thomson · Veterans Medical Research Fdn/San Diego · R01 · FY2020 · DK
Glomerular and Tubular Function in the Diabetic Kidney
$432,346Scott C. Thomson · Veterans Medical Research Fdn/San Diego · R01 · FY2018 · DK
Glomerular and Tubular Function in the Diabetic Kidney
$432,346Scott C. Thomson · Veterans Medical Research Fdn/San Diego · R01 · FY2019 · DK
Glomerular and Tubular Function in the Diabetic Kidney
$432,346Scott C. Thomson · Veterans Medical Research Fdn/San Diego · R01 · FY2021 · DK
Pudendal neuromodulation for urinary and fecal incontinence and sphincter dyssynergia
$431,363Karl B Thor · Dignify Therapeutics, Llc · R44 · FY2021 · NS
Achieving Therapeutic Antigent-Specific Tolerance in Type 1 Diabetes
$431,123Matthias G. Von Herrath · La Jolla Institute For Immunology · U01 · FY2008 · DK
Validation of an In Vitro Human Airway Model for Regulatory Toxicity Testing
$431,027Patrick J Hayden · Mattek Corporation · U44 · FY2017 · ES
Supramolecular Engineering of Ultra-Long-Lasting GLP-1 Depots
$430,375Matthew Webber · University Of Notre Dame · R21 · FY2025 · EB